78 related articles for article (PubMed ID: 23108380)
1. Bioimpedance rise in response to histone deacetylase inhibitor is a marker of mammary cancer cells within a mixed culture of normal breast cells.
Srinivasaraghavan V; Strobl J; Agah M
Lab Chip; 2012 Dec; 12(24):5168-79. PubMed ID: 23108380
[TBL] [Abstract][Full Text] [Related]
2. MCF10A and MDA-MB-231 human breast basal epithelial cell co-culture in silicon micro-arrays.
Nikkhah M; Strobl JS; Schmelz EM; Roberts PC; Zhou H; Agah M
Biomaterials; 2011 Oct; 32(30):7625-32. PubMed ID: 21764441
[TBL] [Abstract][Full Text] [Related]
3. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
4. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
Munster PN; Troso-Sandoval T; Rosen N; Rifkind R; Marks PA; Richon VM
Cancer Res; 2001 Dec; 61(23):8492-7. PubMed ID: 11731433
[TBL] [Abstract][Full Text] [Related]
5. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
6. Effects of trichostatin A, a histone deacetylase inhibitor, on the regulation of apoptosis in H-ras-transformed breast epithelial cells.
Park H; Lee YJ; Kim TH; Lee J; Yoon S; Choi WS; Myung CS; Kim HS
Int J Mol Med; 2008 Nov; 22(5):605-11. PubMed ID: 18949380
[TBL] [Abstract][Full Text] [Related]
7. The cytoskeletal organization of breast carcinoma and fibroblast cells inside three dimensional (3-D) isotropic silicon microstructures.
Nikkhah M; Strobl JS; De Vita R; Agah M
Biomaterials; 2010 Jun; 31(16):4552-61. PubMed ID: 20207413
[TBL] [Abstract][Full Text] [Related]
8. Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.
Park KC; Kim SW; Park JH; Song EH; Yang JW; Chung HJ; Jung HJ; Suh JS; Kwon HJ; Choi SH
Cancer Sci; 2011 Feb; 102(2):343-50. PubMed ID: 21159061
[TBL] [Abstract][Full Text] [Related]
9. Quantification of the heterogeneity in breast cancer cell lines using whole-cell impedance spectroscopy.
Han A; Yang L; Frazier AB
Clin Cancer Res; 2007 Jan; 13(1):139-43. PubMed ID: 17200348
[TBL] [Abstract][Full Text] [Related]
10. Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells.
Rahim R; Strobl JS
Anticancer Drugs; 2009 Sep; 20(8):736-45. PubMed ID: 19584707
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells.
Lee KW; Kim JH; Park JH; Kim HP; Song SH; Kim SG; Kim TY; Jong HS; Jung KH; Im SA; Kim TY; Kim NK; Bang YJ
Anticancer Res; 2006; 26(5A):3429-38. PubMed ID: 17094463
[TBL] [Abstract][Full Text] [Related]
12. Attachment and response of human fibroblast and breast cancer cells to three dimensional silicon microstructures of different geometries.
Nikkhah M; Strobl JS; Agah M
Biomed Microdevices; 2009 Apr; 11(2):429-41. PubMed ID: 19058013
[TBL] [Abstract][Full Text] [Related]
13. Potent in vivo anti-breast cancer activity of IN-2001, a novel inhibitor of histone deacetylase, in MMTV/c-Neu mice.
Joung KE; Min KN; An JY; Kim DK; Kong G; Sheen YY
Cancer Res; 2006 May; 66(10):5394-402. PubMed ID: 16707467
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and primary activity assay of tripeptidomimetics as histone deacetylase inhibitors with linear linker and branched cap group.
Zhang Y; Feng J; Jia Y; Xu Y; Liu C; Fang H; Xu W
Eur J Med Chem; 2011 Nov; 46(11):5387-97. PubMed ID: 21924799
[TBL] [Abstract][Full Text] [Related]
15. Actions of the anti-cancer drug suberoylanilide hydroxamic acid (SAHA) on human breast cancer cytoarchitecture in silicon microstructures.
Strobl JS; Nikkhah M; Agah M
Biomaterials; 2010 Sep; 31(27):7043-50. PubMed ID: 20579727
[TBL] [Abstract][Full Text] [Related]
16. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
Marchion DC; Bicaku E; Daud AI; Richon V; Sullivan DM; Munster PN
J Cell Biochem; 2004 May; 92(2):223-37. PubMed ID: 15108350
[TBL] [Abstract][Full Text] [Related]
17. E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer.
Lu Z; Luo RZ; Peng H; Huang M; Nishmoto A; Hunt KK; Helin K; Liao WS; Yu Y
Oncogene; 2006 Jan; 25(2):230-9. PubMed ID: 16158053
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition.
Yang X; Ferguson AT; Nass SJ; Phillips DL; Butash KA; Wang SM; Herman JG; Davidson NE
Cancer Res; 2000 Dec; 60(24):6890-4. PubMed ID: 11156387
[TBL] [Abstract][Full Text] [Related]
19. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
20. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
Butler LM; Agus DB; Scher HI; Higgins B; Rose A; Cordon-Cardo C; Thaler HT; Rifkind RA; Marks PA; Richon VM
Cancer Res; 2000 Sep; 60(18):5165-70. PubMed ID: 11016644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
